SAN FRANCISCO—Only a minority of patients with Lynch syndrome may be taking aspirin to prevent colorectal cancer despite its proven benefit, according to new research presented at the 2024 ASCO Gastrointestinal Cancers Symposium.
Approximately 3% of CRC is caused by Lynch syndrome, and this proportion increases to 8% in people younger than 50 years of age. Aspirin has demonstrated strong preventive effects, such as a 35% reduction in risk achieved with 600 mg per day for at least two years